Literature DB >> 31493971

US National Trends in the Management and Outcomes of Constrictive Pericarditis: 2005-2014.

Makoto Mori1, Clancy W Mullan1, Syed Usman Bin Mahmood1, Sameh Yousef1, Keith J Pelletier1, Abeel A Mangi1, Arnar Geirsson2.   

Abstract

BACKGROUND: Patient characteristics, trends in the management strategy, and outcomes of patients with constrictive pericarditis have not been characterized at the national scale.
METHODS: Annual trends of patients admitted to hospitals in the United States with constrictive pericarditis were evaluated using the National Inpatient Sample dataset between 2005 and 2014. Poisson regression models adjusting for the US census population estimate were fitted to evaluate trends in the incidence of constrictive pericarditis, isolated pericardiectomy, and cardiopulmonary bypass (CPB) use. Descriptive analyses were performed to compare patient characteristics and in-hospital mortality rates between surgically and medically managed cohorts.
RESULTS: During 2005-2014, 29,487 patients were admitted with constrictive pericarditis. Sixteen percent underwent isolated pericardiectomy. The prevalence of constrictive pericarditis remained stable between 2005 and 2014 at 9-10 cases per million, but proportion of patients undergoing isolated pericardiectomy decreased from 18% in 2005 to 15% in 2014 (P = 0.001 for trend). CPB use increased from 15% to 29% (P < 0.001). Compared with medically managed patients, the pericardiectomy cohort was younger (age 57 vs 61 years, P < 0.001), less likely to be female (25% vs 41%, P < 0.001), and harboured fewer comorbidities. In-hospital mortality was 7.3% for those undergoing pericardiectomy and 6.8% for a medically managed cohort (P = 0.58) and operative mortality was stable across years (P = 0.99 for trend).
CONCLUSIONS: The prevalence of constrictive pericarditis remained stable between 2005 and 2014 at 9-10 cases per million. Surgical management was infrequent, with younger and less comorbid patients being more likely to be managed operatively. Increasing use of CPB without a change in operative mortality highlights the persisting challenge of this complex disease.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31493971     DOI: 10.1016/j.cjca.2019.05.015

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

1.  A case report of pericardial constriction with coexisting severe left main coronary artery disease.

Authors:  Saman Ostad Karampour; Tara L Sedlak; Christina L Luong; Joel E Price; Nathan W Brunner
Journal:  Eur Heart J Case Rep       Date:  2022-07-02

2.  The Clinical Efficacy of Cedilanid and Isosorbide Dinitrate plus Pericardial Dissection for Chronic Constrictive Pericarditis in the Elderly and Its Influence on Plasma Endothelin, Atrial Natriuretic Peptide, and Systemic Immune-Inflammation Index.

Authors:  Yan Shao; Zhirong Yang; Lu Yin; Qiang Wang; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-22       Impact factor: 2.650

3.  Diagnosis and treatment of effusive-constrictive pericarditis: a case report.

Authors:  Yousif Al-Saiegh; Jenna Spears; Tim Barry; Christopher Lee; Howard Haber; Sheldon Goldberg
Journal:  Eur Heart J Case Rep       Date:  2021-05-08

Review 4.  Constrictive Pericarditis: A Commonly Missed Cause of Treatable Diastolic Heart Failure.

Authors:  Pradnya Brijmohan Bhattad; Vinay Jain
Journal:  Cureus       Date:  2020-05-08

5.  Constrictive pericarditis with pericardial calcification.

Authors:  Kevin R An; Steve K Singh
Journal:  CMAJ       Date:  2021-06-07       Impact factor: 8.262

6.  Fifteen-year experience with pericardiectomy at a tertiary referral center.

Authors:  Zainab Faiza; Anjali Prakash; Niharika Namburi; Bailey Johnson; Lava Timsina; Lawrence S Lee
Journal:  J Cardiothorac Surg       Date:  2021-06-22       Impact factor: 1.637

7. 

Authors:  Kevin R An; Steve K Singh
Journal:  CMAJ       Date:  2021-08-23       Impact factor: 8.262

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.